

Technology Advisory Interests Register

Topic: Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (Review of TA909) [ID6434]

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Prof. Sofia Dias	TAC Committee Member	Indirect – Professional	Sofia is the Director of the University of York Technology Assessment Group who is the EAG for this topic. However, was not directly involved with this assessment.	06/02/2025 13/06/2025	It was agreed that Sofia's declaration would not prevent them from participating in discussions on this appraisal
David Meads	TAC Committee Member	Indirect – Professional	David works for the University of Leeds who have received funding from Takeda for research in an unrelated area.	11/02/2025 15/06/2025	It was agreed that David's declaration would not prevent them from participating in discussions on this appraisal
Dr Robert Hodgson	TAC Committee Member	Direct – Professional	Robert is part of the EAG team for ID6434.	10/02/2025 19/06/2025	It was agreed that Robert's declaration would prevent them from participating in discussions on this appraisal
Professor Alastair Greystoke	Clinical Expert	Indirect – Professional	Alistair has received consultancy and speaker fees for: Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, MSD, Novartis, Pfizer and Roche for treatments in SCLC and NSCLC, and Takada.	12/03/2025	It was agreed that Alastair's declaration would not prevent them from providing expert advice to the committee

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Shobhit Bajjal	Clinical Expert	Indirect – Professional	Shobhit has received honoraria from Pfizer for Consultancy work	12/03/2025 09/07/2025	It was agreed that Shobhit's declaration would not prevent them from providing expert advice to the committee